newsfilter
← Latest News
CNBC·

Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says

"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.